Synthetic Biology Startup Acquires AI Platform To Disrupt The Drug Industry

Synthetic biology company AbSci’s recent acquisition of the artificial intelligence platform, Denovium, could help get novel therapeutics to patients more quickly

Read the full post on Forbes - Healthcare

John Cumbers, Contributor